Literature DB >> 30108928

Rational design and characterization of a DNA/HDAC dual-targeting inhibitor containing nitrogen mustard and 2-aminobenzamide moieties.

Rui Xie1, Pingwah Tang1, Qipeng Yuan1.   

Abstract

Histone deacetylases (HDACs) play a key role not only in gene expression but also in DNA repair. Herein, we report the rational design and characterization of a compound named chlordinaline containing nitrogen mustard and 2-aminobenzamide moieties as a DNA/HDAC dual-targeting inhibitor. Chlordinaline exhibited moderate total HDAC inhibitory activity. The HDAC isoform selectivity assay indicated that chlordinaline mostly inhibits HDAC3. Chlordinaline exhibited both DNA and HDAC inhibitory activities and showed potent antiproliferative activity against all the six test cancer cell lines with IC50 values of as low as 3.1-14.2 μM, which is significantly more potent than reference drugs chlorambucil and tacedinaline. Chlordinaline could induce the apoptosis and G2/M phase cell cycle arrest of A375 cancer cells. This study demonstrates that combining nitrogen mustard and 2-aminobenzamide moieties into one molecule is an effective method to obtain DNA/HDAC dual-targeting inhibitors as potent antitumor agents. Chlordinaline as the first example of such DNA/HDAC dual-targeting inhibitors could be a promising candidate for cancer therapy and could also be a lead compound for further optimization.

Entities:  

Year:  2017        PMID: 30108928      PMCID: PMC6083786          DOI: 10.1039/c7md00476a

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  44 in total

Review 1.  Histone deacetylase inhibitors (HDACIs). Structure--activity relationships: history and new QSAR perspectives.

Authors:  Eleni Pontiki; Dimitra Hadjipavlou-Litina
Journal:  Med Res Rev       Date:  2010-02-16       Impact factor: 12.944

Review 2.  Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.

Authors:  Himashinie V K Diyabalanage; Michael L Granda; Jacob M Hooker
Journal:  Cancer Lett       Date:  2012-09-29       Impact factor: 8.679

3.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.

Authors:  John R Somoza; Robert J Skene; Bradley A Katz; Clifford Mol; Joseph D Ho; Andy J Jennings; Christine Luong; Andrew Arvai; Joseph J Buggy; Ellen Chi; Jie Tang; Bi-Ching Sang; Erik Verner; Robert Wynands; Ellen M Leahy; Douglas R Dougan; Gyorgy Snell; Marc Navre; Mark W Knuth; Ronald V Swanson; Duncan E McRee; Leslie W Tari
Journal:  Structure       Date:  2004-07       Impact factor: 5.006

4.  Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.

Authors:  Wilko Weichert; Annika Röske; Silvia Niesporek; Aurelia Noske; Ann-Christin Buckendahl; Manfred Dietel; Volker Gekeler; Markus Boehm; Thomas Beckers; Carsten Denkert
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

5.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.

Authors:  Ping Zhu; Elke Martin; Jörg Mengwasser; Peter Schlag; Klaus-Peter Janssen; Martin Göttlicher
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

6.  A novel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and in vitro cytotoxicity.

Authors:  James P Parker; Hassan Nimir; Darren M Griffith; Brian Duff; Anthony J Chubb; Marian P Brennan; Maria P Morgan; Denise A Egan; Celine J Marmion
Journal:  J Inorg Biochem       Date:  2013-03-29       Impact factor: 4.155

7.  A history of cancer chemotherapy.

Authors:  Vincent T DeVita; Edward Chu
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 8.  The DNA damage response and cancer therapy.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

9.  Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Authors:  W Weichert; A Röske; V Gekeler; T Beckers; C Stephan; K Jung; F R Fritzsche; S Niesporek; C Denkert; M Dietel; G Kristiansen
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

10.  Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.

Authors:  Yang Hai; David W Christianson
Journal:  Nat Chem Biol       Date:  2016-07-25       Impact factor: 15.040

View more
  2 in total

1.  Hybrid inhibitors of DNA and HDACs remarkably enhance cytotoxicity in leukaemia cells.

Authors:  Yoojin Song; Sun You Park; Zhexue Wu; Kwang-Hyeon Liu; Young Ho Seo
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 2.  Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.

Authors:  Robert Jenke; Nina Reßing; Finn K Hansen; Achim Aigner; Thomas Büch
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.